Ayala Pharmaceuticals Revenue

In the year 2023, Ayala Pharmaceuticals had annual revenue of $13.00K, down -98.12%.

Revenue

13.00K

Revenue Growth

-98.12%

P/S Ratio

2,753.34

Revenue / Employee

619.05

Employees

Market Cap

35.79M

Revenue Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	13.00K	-679.00K	-98.12%
Dec 31, 2022	692.00K	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Ayala Pharmaceuticals News

1 year ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline - Business Wire
1 year ago - OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline - Business Wire
2 years ago - Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - GlobeNewsWire
2 years ago - Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome - GlobeNewsWire
2 years ago - Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors - Business Wire
2 years ago - Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals - Business Wire
3 years ago - Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 - GlobeNewsWire
3 years ago - Ayala Pharmaceuticals Announces Closing of Merger with Biosight - GlobeNewsWire

More News